Co-administration of certain DNA vaccine combinations expressing different H5N1 influenza virus antigens can be beneficial or detrimental to immune protection

Vaccine

Volumn 30, Issue 3, 2012, Pages 626-636

  Patel, Ami ^a,b   Gray, Michael ^a   Li, Yan ^a,b   Kobasa, Darwyn ^a,b   Yao, Xiaojian ^b   Kobinger, Gary P ^a,b  

^a Public Health Agency of Canada   (Canada)

^b UNIVERSITY OF MANITOBA   (Canada)

Author keywords

Antibody response; Antigen combination; Antigen competition; Cell mediated response; DNA vaccine; H5N1 influenza; Multivalent vaccine

Indexed keywords

ADENOVIRUS VECTOR; DNA VACCINE; INFLUENZA VACCINE; VIRUS ANTIGEN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CELLULAR IMMUNITY; CONTROLLED STUDY; DRUG DOSE COMPARISON; INFLUENZA A (H5N1); INFLUENZA VACCINATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; SINGLE DRUG DOSE; SURVIVAL RATE; T LYMPHOCYTE; WEIGHT REDUCTION;

ANIMALS; ANTIBODIES, VIRAL; ANTIGENS, VIRAL; DISEASE MODELS, ANIMAL; HEMAGGLUTININ GLYCOPROTEINS, INFLUENZA VIRUS; INFLUENZA A VIRUS, H5N1 SUBTYPE; INFLUENZA VACCINES; MICE; MICE, INBRED BALB C; NEURAMINIDASE; ORTHOMYXOVIRIDAE INFECTIONS; RNA-BINDING PROTEINS; SURVIVAL ANALYSIS; T-LYMPHOCYTES; VACCINES, DNA; VIRAL CORE PROTEINS; VIRAL MATRIX PROTEINS; VIRAL PROTEINS;

EID: 84355166382     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2011.11.017     Document Type: Article

References (39)

1. WHO Avian Influenza 2010, Available from: http://www.who.int/csr/disease/avian_influenza/en/ [cited 2010 July 20, 2009].
2. Yang Y., Halloran M.E., Sugimoto J.D., Longini I.M. Detecting human-to-human transmission of avian influenza A (H5N1). Emerg Infect Dis 2007, 13(September (9)):1348-1353.
3. WHO. Avian influenza - situation in Pakistan - update 2 [Electronic]; 2008. Available from: [cited 2009 February 18, 2009]. http://www.who.int/csr/don/2008_04_03/en/index.html.
4. Wang H., Feng Z., Shu Y., Yu H., Zhou L., Zu R., et al. Probable limited person-to-person transmission of highly pathogenic avian influenza A (H5N1) virus in China. Lancet 2008, 371(April (9622)):1427-1434.
5. Lalor P.A., Webby R.J., Morrow J., Rusalov D., Kaslow D.C., Rolland A., et al. Plasmid DNA-based vaccines protect mice and ferrets against lethal challenge with A/Vietnam/1203/04 (H5N1) influenza virus. J Infect Dis 2008, 197(June (12)):1643-1652.
6. Zheng L., Wang F., Yang Z., Chen J., Chang H., Chen Z. A single immunization with HA DNA vaccine by electroporation induces early protection against H5N1 avian influenza virus challenge in mice. BMC Infect Dis 2009, 9:17.
7. Abt M., de Jonge J., Laue M., Wolff T. Improvement of H5N1 influenza vaccine viruses: influence of internal gene segments of avian and human origin on production and hemagglutinin content. Vaccine 2011, 29(July (32)):5153-5162.
8. Welsh R.M., Fujinami R.S. Pathogenic epitopes, heterologous immunity and vaccine design. Nat Rev Microbiol 2007, 5(July (7)):555-563.
9. Kuszewski K., Brydak L. The epidemiology and history of influenza. Biomed Pharmacother 2000, 54(May (4)):188-195.
10. Woodland D.L., Hogan R.J., Zhong W. Cellular immunity and memory to respiratory virus infections. Immunol Res 2001, 24(1):53-67.
11. Wiley J.A., Hogan R.J., Woodland D.L., Harmsen A.G. Antigen-specific CD8(+) T cells persist in the upper respiratory tract following influenza virus infection. J Immunol 2001, 167(September (6)):3293-3299.
12. Epstein S.L., Tumpey T.M., Misplon J.A., Lo C.Y., Cooper L.A., Subbarao K., et al. DNA vaccine expressing conserved influenza virus proteins protective against H5N1 challenge infection in mice. Emerg Infect Dis 2002, 8(August (8)):796-801.
13. Rao S.S., Kong W.P., Wei C.J., Van Hoeven N., Gorres J.P., Nason M., et al. Comparative efficacy of hemagglutinin, nucleoprotein, and matrix 2 protein gene-based vaccination against H5N1 influenza in mouse and ferret. PLoS One 2009, 5(3):e9812.
14. Chang H., Huang C., Wu J., Fang F., Zhang W., Wang F., et al. A single dose of DNA vaccine based on conserved H5N1 subtype proteins provides protection against lethal H5N1 challenge in mice pre-exposed to H1N1 influenza virus. Virol J 2010, 7:197.
15. Kodihalli S., Goto H., Kobasa D.L., Krauss S., Kawaoka Y., Webster R.G. DNA vaccine encoding hemagglutinin provides protective immunity against H5N1 influenza virus infection in mice. J Virol 1999, 73(March (3)):2094-2098.
16. Jiang Y., Yu K., Zhang H., Zhang P., Li C., Tian G., et al. Enhanced protective efficacy of H5 subtype avian influenza DNA vaccine with codon optimized HA gene in a pCAGGS plasmid vector. Antiviral Res 2007, 75(September (3)):234-241.
17. Patel A., Tran K., Gray M., Li Y., Ao Z., Yao X., et al. Evaluation of conserved and variable influenza antigens for immunization against different isolates of H5N1 viruses. Vaccine 2009, 27(May (23)):3083-3089.
18. Richardson J.S., Yao M.K., Tran K.N., Croyle M.A., Strong J.E., Feldmann H., et al. Enhanced protection against Ebola virus mediated by an improved adenovirus-based vaccine. PLoS One 2009, 4(4):e5308.
19. Zhi Y., Kobinger G.P., Jordan H., Suchma K., Weiss S.R., Shen H., et al. Identification of murine CD8 T cell epitopes in codon-optimized SARS-associated coronavirus spike protein. Virology 2005, 335(April (1)):34-45.
20. Deck R.R., DeWitt C.M., Donnelly J.J., Liu M.A., Ulmer J.B. Characterization of humoral immune responses induced by an influenza hemagglutinin DNA vaccine. Vaccine 1997, 15(January (1)):71-78.
21. de Jong J.C., Palache A.M., Beyer W.E., Rimmelzwaan G.F., Boon A.C., Osterhaus A.D. Haemagglutination-inhibiting antibody to influenza virus. Dev Biol (Basel) 2003, 115:63-73.
22. Berger R., Just M., Gluck R. Interference between strains in live virus vaccines, I: combined vaccination with measles, mumps and rubella vaccine. J Biol Stand 1988, 16(October (4)):269-273.
23. Jalil F., Zaman S., Carlsson B., Glass R.I., Kapikian A.Z., Mellander L., et al. Immunogenicity and reactogenicity of rhesus rotavirus vaccine given in combination with oral or inactivated poliovirus vaccines and diphtheria-tetanus-pertussis vaccine. Trans R Soc Trop Med Hyg 1991, 85(March-April (2)):292-296.
24. Holman D.H., Wang D., Raja N.U., Luo M., Moore K.M., Woraratanadharm J., et al. Multi-antigen vaccines based on complex adenovirus vectors induce protective immune responses against H5N1 avian influenza viruses. Vaccine 2008, 26(May (21)):2627-2639.
25. Tatsis N., Tesema L., Robinson E.R., Giles-Davis W., McCoy K., Gao G.P., et al. Chimpanzee-origin adenovirus vectors as vaccine carriers. Gene Ther 2006, 13(March (5)):421-429.
26. Yashima S., Yoshizaki S., Shinoda K., Yoshida A., Kondo A., Mizuguchi H., et al. Co-administration of viral vector-based vaccines suppresses antigen-specific effector CD8T cells. Vaccine 2010, 28(April (18)):3257-3264.
27. Berger R., Just M. Interference between strains in live virus vaccines. II: combined vaccination with varicella and measles-mumps-rubella vaccine. J Biol Stand 1988, 16(October (4)):275-279.
28. Zhang T., Xu Y., Qiao L., Wang Y., Wu X., Fan D., et al. Trivalent human papillomavirus (HPV) VLP vaccine covering HPV type 58 can elicit high level of humoral immunity but also induce immune interference among component types. Vaccine 2010, 28(April (19)):3479-3487.
29. Sharma A., Bangari D.S., Tandon M., Hogenesch H., Mittal S.K. Evaluation of innate immunity and vector toxicity following inoculation of bovine, porcine or human adenoviral vectors in a mouse model. Virus Res 2011 Oct, 153(1):134-142.
30. Bangari D.S., Mittal S.K. Porcine adenovirus serotype 3 internalization is independent of CAR and alphavbeta3 or alphavbeta5 integrin. Virology 2005, 332(February (1)):157-166.
31. Johansson B.E., Kilbourne E.D. Dissociation of influenza virus hemagglutinin and neuraminidase eliminates their intravirionic antigenic competition. J Virol 1993, 67(October (10)):5721-5723.
32. Johansson B.E., Kilbourne E.D. Immunization with dissociated neuraminidase, matrix, and nucleoproteins from influenza A virus eliminates cognate help and antigenic competition. Virology 1996, 225(November (1)):136-144.
33. Hammerl P., Weger R., Thalhamer J. Antigenic competition in the immune response against protein mixtures: strain-specific non-immunogenicity of Escherichia coli antigens. Mol Immunol 1988, 25(March (3)):313-320.
34. Taussig M.J., Mozes E., Shearer G.M., Sela M. Antigenic competition and genetic control of the immune response. A hypothesis for intramolecular competition. Cell Immunol 1973, 8(August (2)):299-310.
35. Kedl R.M., Rees W.A., Hildeman D.A., Schaefer B., Mitchell T., Kappler J., et al. T cells compete for access to antigen-bearing antigen-presenting cells. J Exp Med 2000, 192(October (8)):1105-1113.
36. Kedl R.M., Schaefer B.C., Kappler J.W., Marrack P. T cells down-modulate peptide-MHC complexes on APCs in vivo. Nat Immunol 2002, 3(January (1)):27-32.
37. Haigh O., Kattenbelt J., Cochrane M., Thomson S., Gould A., Tindle R. Hepatitis B surface antigen fusions delivered by DNA vaccination elicit CTL responses to human papillomavirus oncoproteins associated with tumor protection. Cancer Gene Ther 2011, 17(October (10)):708-720.
38. Patel V., Valentin A., Kulkarni V., Rosati M., Bergamaschi C., Jalah R., et al. Long-lasting humoral and cellular immune responses and mucosal dissemination after intramuscular DNA immunization. Vaccine 2011, 28(July (30)):4827-4836.
39. Gurunathan S., Klinman D.M., Seder R.A. DNA vaccines: immunology, application, and optimization. Annu Rev Immunol 2000, 18:927-974.